Myocardial Solutions’ software platform, MyoStrain, was featured in a new Journal of Cardiovascular Magnetic Resonance publication evaluating a multiparametric assessment of left ventricular hypertrophy (LVH). LVH, which can be a result of an array of diseases and conditions, makes determining the..
A recent study published in the Journal of Cardiovascular Magnetic Resonance featured Myocardial Solutions’ technology MyoStrain, where MyoStrain was used to examine myocardial tissue function in Wilson Disease (WD) patients. WD, a storage disease that results in...
A new pivotal article validated Myocardial Solutions technology MyoStrain® (fSENC) for the early detection and prediction of cardiotoxicity (heart damage). The article was published in published in Circulation: Cardiovascular Imaging, Journal of the American Heart Association–one of the most ...
Most of the funds were raised from individuals and family offices. The Company’s post financing valuation is $93.2M. Among the business consequences of COVID...
Myocardial Solutions (“MSI”) technologies MyoStrain® (fSENC) was featured in a newly published article exploring the effectiveness of cardiovascular magnetic resonance (CMR) and segmental strain to detect ischemia in patients suspected of obstructive coronary artery disease (CAD)...
